Tags

Type your tag names separated by a space and hit enter

Improved discrimination of autopsy-confirmed Alzheimer's disease (AD) from non-AD dementias using CSF P-tau(181P).
Neurochem Int. 2009 Sep; 55(4):214-8.NI

Abstract

To establish diagnostic accuracy (acc) and optimal cut-off levels of CSF tau phosphorylated at threonine 181 (P-tau(181P)) for discriminating Alzheimer's disease (AD) from non-AD dementias in autopsy-confirmed dementia patients, CSF levels of beta-amyloid peptide (Abeta(1-42)), total tau protein (T-tau) and P-tau(181P) from patients with definite AD (n=95) and non-AD dementias (n=50) were determined with single-parameter ELISA kits. Optimal P-tau(181P) cut-off levels for differentiating AD from pooled non-AD dementias, dementia with Lewy bodies (DLB) and frontotemporal dementia (FTD) were 50.4pg/mL (acc=0.73), 52.8pg/mL (acc=0.73) and 35.3pg/mL (acc=0.90), respectively. The optimal CSF P-tau(181P) cut-off level for discriminating AD from non-AD dementias was 50.4pg/mL. Optimal CSF P-tau(181P) cut-off levels differed between non-AD diagnostic dementia categories.

Authors+Show Affiliations

Department of Neurology and Memory Clinic, Middelheim General Hospital (ZNA), Antwerp, Belgium; Department of Neurology, University Medical Center Groningen, Groningen, The Netherlands.No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

19524111

Citation

Koopman, Karen, et al. "Improved Discrimination of Autopsy-confirmed Alzheimer's Disease (AD) From non-AD Dementias Using CSF P-tau(181P)." Neurochemistry International, vol. 55, no. 4, 2009, pp. 214-8.
Koopman K, Le Bastard N, Martin JJ, et al. Improved discrimination of autopsy-confirmed Alzheimer's disease (AD) from non-AD dementias using CSF P-tau(181P). Neurochem Int. 2009;55(4):214-8.
Koopman, K., Le Bastard, N., Martin, J. J., Nagels, G., De Deyn, P. P., & Engelborghs, S. (2009). Improved discrimination of autopsy-confirmed Alzheimer's disease (AD) from non-AD dementias using CSF P-tau(181P). Neurochemistry International, 55(4), 214-8. https://doi.org/10.1016/j.neuint.2009.02.017
Koopman K, et al. Improved Discrimination of Autopsy-confirmed Alzheimer's Disease (AD) From non-AD Dementias Using CSF P-tau(181P). Neurochem Int. 2009;55(4):214-8. PubMed PMID: 19524111.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Improved discrimination of autopsy-confirmed Alzheimer's disease (AD) from non-AD dementias using CSF P-tau(181P). AU - Koopman,Karen, AU - Le Bastard,Nathalie, AU - Martin,Jean-Jacques, AU - Nagels,Guy, AU - De Deyn,Peter P, AU - Engelborghs,Sebastiaan, Y1 - 2009/03/05/ PY - 2008/11/27/received PY - 2009/02/09/revised PY - 2009/02/25/accepted PY - 2009/6/16/entrez PY - 2009/6/16/pubmed PY - 2009/9/3/medline SP - 214 EP - 8 JF - Neurochemistry international JO - Neurochem Int VL - 55 IS - 4 N2 - To establish diagnostic accuracy (acc) and optimal cut-off levels of CSF tau phosphorylated at threonine 181 (P-tau(181P)) for discriminating Alzheimer's disease (AD) from non-AD dementias in autopsy-confirmed dementia patients, CSF levels of beta-amyloid peptide (Abeta(1-42)), total tau protein (T-tau) and P-tau(181P) from patients with definite AD (n=95) and non-AD dementias (n=50) were determined with single-parameter ELISA kits. Optimal P-tau(181P) cut-off levels for differentiating AD from pooled non-AD dementias, dementia with Lewy bodies (DLB) and frontotemporal dementia (FTD) were 50.4pg/mL (acc=0.73), 52.8pg/mL (acc=0.73) and 35.3pg/mL (acc=0.90), respectively. The optimal CSF P-tau(181P) cut-off level for discriminating AD from non-AD dementias was 50.4pg/mL. Optimal CSF P-tau(181P) cut-off levels differed between non-AD diagnostic dementia categories. SN - 1872-9754 UR - https://www.unboundmedicine.com/medline/citation/19524111/Improved_discrimination_of_autopsy_confirmed_Alzheimer's_disease__AD__from_non_AD_dementias_using_CSF_P_tau_181P__ L2 - https://linkinghub.elsevier.com/retrieve/pii/S0197-0186(09)00078-3 DB - PRIME DP - Unbound Medicine ER -